CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Glofitamab 和 epcoritamab 用于大 B 细胞淋巴瘤：一项关于疗效、耐受性及治疗序贯影响的英国真实世界回顾性分析
英文原题：Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.
查看英文原题
Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Glofitamab和epcoritamab是获批用于复发/难治性大B细胞淋巴瘤（RR LBCL）的CD3xCD20双特异性抗体，但真实世界数据有限。数据收集自英国34个中心的332例患者（219例glofitamab，113例epcoritamab）（2023年11月至2025年5月）。该高危队列中位既往治疗线数为2线；179例（55%）原发难治性疾病；81例（25%）ECOG ≥2；152例（50%）既往接受过CAR-T 细胞治疗；232例（78%）不符合关键试验入组标准。7例患者在治疗开始前死亡，1例患者尚未开始治疗，在324例接受治疗的患者中，28%发生细胞因子释放综合征（CRS），主要为1/2级（82/90）。总缓解率（ORR）和完全缓解率（CRR）分别为43%和24%，而在符合试验入组标准的患者中，CRR为43%。
在中位10.0个月随访时（IQR 5.3-15.0），中位无进展生存期（PFS）为3.1个月（95%置信区间[CI]，2.5-4.2），中位总生存期（OS）为6.9个月（95% CI，4.9-10.8）。对于未完成第2周期的患者，6个月OS为4%（95% CI 1-11%）。中位完全缓解持续时间未达到。对既往治疗线数难治（HR 2.89，95% CI 1.73-4.81，p=0.007）、LDH升高（HR 2.62，95% CI 1.74-3.93，p=0.001）、6个月内暴露于苯达莫司汀（HR 1.62，95% CI 1.14-2.30，p=0.007）以及ECOG 1（HR 2.70，95% CI 1.52-4.79，p=0.001）或2（HR 6.49，95% CI 3.47-12.01，p。
展开英文摘要原文
Glofitamab and epcoritamab are CD3xCD20 bispecific antibodies licensed for relapsed/refractory large B cell lymphoma (RR LBCL), yet real-world data are limited. Data were collected from 332 patients (219 glofitamab, 113 epcoritamab) across 34 UK centres (November 2023-May 2025).
This high-risk cohort had median 2 prior lines of treatment; 179 (55%) primary refractory disease; 81 (25%) ECOG ≥2; 152 (50%) prior Chimeric Antigen Receptor T-cell therapy; and 232 (78%) pivotal-trial ineligible. 7 patients died before treatment initiation, 1 patient was yet to start treatment, of 324 treated patients, 28% had cytokine release syndrome (CRS), predominately grade 1/2 (82/90).
Overall response rate (ORR) and complete response rate (CRR) were 43% and 24%, respectively, while for trialeligible patients the CRR was 43%. At a median 10. 0 months follow-up (IQR 5. 3-15. 0), median progression-free survival (PFS) was 3. 1 months (95% confidence interval [CI], 2. 5-4. 2), median overall survival (OS) was 6. 9 months (95% CI, 4. 9-10. 8). For patients not completing cycle 2, 6-month OS was 4% (95% CI 1-11%).
Median duration of complete response was not reached. Refractoriness to prior line of treatment (HR 2. 89, 95% CI 1. 73-4. 81, p=0. 007), elevated LDH (HR 2. 62, 95% CI 1. 74-3. 93. p=0. 001), bendamustine exposure within 6 months (HR 1. 62, 95% CI 1. 14-2. 30, p=0. 007) and ECOG 1 (HR 2. 70, 95% CI 1. 52-4. 79, p=0. 001) or 2 (HR 6. 49, 95% CI 3. 47-12. 01, p.
论文信息
- 作者
- Osborne W、Haynes E、Wilson W、Ediriwickrema K、Paterson J、Menne T、El-Sharkawi D、Chan LY
- 单位
- Newcastle Upon Tyne NHS Foundation Trust, Haematology, Newcastle-Upon-Tyne, UK; Newcastle University, Newcastle-Upon-Tyne. wendy.osborne3@nhs.net.United Kingdom
- 期刊
- Haematologica2026 May 14
- 原文标识
- PubMed 42131938 · DOI 10.3324/haematol.2026.300569